<div id="readability-page-1"><p>Cytokinetics (NASDAQ:CYTK - Get Free Report) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported ($1.12) earnings per share for the quarter, beating analysts' consensus estimates of ($1.34) by $0.22, Zacks reports. The company had revenue of $66.77 million for the quarter, compared to the consensus estimate of $1.95 million. During the same quarter in the previous year, the business earned ($1.31) EPS. The company's quarterly revenue was up 26727.3% compared to the same quarter last year.</p><h2>Cytokinetics Price Performance</h2><ul><li>Analysts Think There's Still Time to Get in on Edgewise, Up 332%</li></ul><p>NASDAQ:CYTK traded down $1.14 during trading hours on Friday, hitting $34.11. 2,104,845 shares of the company were exchanged, compared to its average volume of 1,250,101. The stock has a market capitalization of $4.07 billion, a price-to-earnings ratio of -6.69 and a beta of 0.64. Cytokinetics has a 52-week low of $29.31 and a 52-week high of $59.39. The company's 50 day moving average price is $34.88 and its 200-day moving average price is $38.76. </p><h2>Insider Activity at Cytokinetics</h2><p>In other Cytokinetics news, Director Edward M. Md Kaye sold 3,636 shares of the business's stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $32.10, for a total transaction of $116,715.60. Following the sale, the director owned 29,658 shares of the company's stock, valued at approximately $952,021.80. The trade was a 10.92% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this link. Also, EVP Fady Ibraham Malik sold 2,000 shares of the business's stock in a transaction that occurred on Tuesday, August 5th. The stock was sold at an average price of $36.34, for a total transaction of $72,680.00. Following the sale, the executive vice president directly owned 140,610 shares in the company, valued at approximately $5,109,767.40. This represents a 1.40% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 39,749 shares of company stock worth $1,350,617 in the last 90 days. 2.70% of the stock is owned by insiders. </p><h2>Institutional Trading of Cytokinetics</h2><ul><li>Want Diversified Upside in Biotechnology? Check out LABU</li></ul><p>A hedge fund recently raised its stake in Cytokinetics stock. Cetera Investment Advisers raised its holdings in shares of  Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 12.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 6,635 shares of the biopharmaceutical company's stock after acquiring an additional 731 shares during the period. Cetera Investment Advisers' holdings in Cytokinetics were worth $219,000 at the end of the most recent quarter. </p><h2>Analyst Ratings Changes</h2><p>A number of brokerages recently weighed in on CYTK. Raymond James Financial began coverage on shares of Cytokinetics in a report on Wednesday, July 30th. They set a &#34;market perform&#34; rating for the company. Mizuho cut their target price on shares of Cytokinetics from $103.00 to $84.00 and set an &#34;outperform&#34; rating on the stock in a research report on Thursday, May 29th. Citigroup cut their target price on shares of Cytokinetics from $80.00 to $77.00 and set a &#34;buy&#34; rating on the stock in a research report on Friday. UBS Group cut their target price on shares of Cytokinetics from $47.00 to $41.00 and set a &#34;neutral&#34; rating on the stock in a research report on Friday, May 2nd. Finally, Bank of America cut their target price on shares of Cytokinetics from $62.00 to $54.00 and set a &#34;neutral&#34; rating on the stock in a research report on Tuesday, April 15th. Four equities research analysts have rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock  has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $70.69.</p><p><b>Read Our Latest Analysis on Cytokinetics</b></p><h2>About Cytokinetics</h2> (Get Free Report)<p>Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Cytokinetics</li><li>CD Calculator: Certificate of Deposit Calculator </li><li>Rocket Lab Reports Q2 Results: Is the Bull Thesis Still Intact?</li><li>Investing in the High PE Growth Stocks </li><li>Trump GLP-1 Pilot Program Could Boost Novo Nordisk &amp; Eli Lilly</li><li>What is the Dogs of the Dow Strategy? Overview and Examples</li><li>Now Is a Great Time to Buy Cheniere Energy: New High Expected</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1lUSw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1lUSw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Cytokinetics Right Now?</h2><p>Before you consider Cytokinetics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cytokinetics wasn't on the list.</p><p>While Cytokinetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CYTK

<p>Cytokinetics (NASDAQ:CYTK) reported quarterly earnings of ($1.12) EPS, surpassing estimates of ($1.34) by $0.22. The company generated $66.77 million in revenue, significantly exceeding the $1.95 million forecast, marking a 26727.3% increase year-over-year. The stock traded down to $34.11, with a market cap of $4.07 billion. Insider trading activity included sales by Director Edward M. Md Kaye and EVP Fady Ibraham Malik. Analyst ratings show a consensus of "Moderate Buy" with an average price target of $70.69.</p>

Cytokinetics (NASDAQ:CYTK) Issues Earnings Results, Beats Expectations By $0.22 EPS